PA
NTLA icon

Parallel Advisors’s Intellia Therapeutics NTLA Stock Holding History

Parallel Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.5K Hold
618
– – ﹤0.01% 2933
2026
Q1 		$7.92K Hold
618
– – ﹤0.01% 2859
2025
Q4 		$5.56K Hold
618
– – ﹤0.01% 2812
2025
Q3 		$10.7K Hold
618
– – ﹤0.01% 2511
2025
Q2 		$5.8K Buy
618
+380
+160% +$3.12K ﹤0.01% 2685
2025
Q1 		$1.69K Sell
238
-85
-26% -$859 ﹤0.01% 3022
2024
Q4 		$3.77K Buy
323
+317
+5,283% +$4.95K ﹤0.01% 2741
2024
Q3 		$123 Sell
6
-33
-85% -$761 ﹤0.01% 3329
2024
Q2 		$873 Sell
39
-36
-48% -$857 ﹤0.01% 2994
2024
Q1 		$2.06K Sell
75
-192
-72% -$5.33K ﹤0.01% 2819
2023
Q4 		$8.14K Sell
267
-22
-8% -$632 ﹤0.01% 2364
2023
Q3 		$9.14K Buy
289
+50
+21% +$1.94K ﹤0.01% 2246
2023
Q2 		$9.75K Sell
239
-49
-17% -$1.99K ﹤0.01% 2178
2023
Q1 		$10.7K Buy
288
+114
+66% +$4.47K ﹤0.01% 2097
2022
Q4 		$6.07K Sell
174
-4
-2% -$190 ﹤0.01% 2246
2022
Q3 		$10K Buy
178
+1
+0.6% +$62 ﹤0.01% 2001
2022
Q2 		$9K Sell
177
-23
-12% -$1.17K ﹤0.01% 2041
2022
Q1 		$14K Buy
200
+1
+0.5% +$85 ﹤0.01% 1869
2021
Q4 		$24K Sell
199
-66
-25% -$8.27K ﹤0.01% 1696
2021
Q3 		$36K Buy
265
+141
+114% +$21.3K ﹤0.01% 1436
2021
Q2 		$20K Sell
124
-26
-17% -$2.02K ﹤0.01% 1687
2021
Q1 		$12K Buy
150
+115
+329% +$7.72K ﹤0.01% 1848
2020
Q4 		$2K Buy
+35
New +$1.27K ﹤0.01% 2331
2017
Q4 		– Sell
-1,000
Closed -$20K – 2117
2017
Q3 		$20K Buy
+1,000
New +$18.8K ﹤0.01% 1007

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Parallel Advisors's NTLA Position: Q2 2026 in Review

Parallel Advisors held its Intellia Therapeutics (NTLA) position steady in Q2 2026 at 618 shares worth $10.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2933.

Parallel Advisors first reported a position in NTLA in Q3 2017 and has held it in 24 quarters since. The position peaked at $36K in Q3 2021. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Parallel Advisors held 618 shares of Intellia Therapeutics worth $10.5K as of Q2 2026.
  • Parallel Advisors left its Intellia Therapeutics share count unchanged in Q2 2026.
  • Intellia Therapeutics made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #2933 holding.
  • Parallel Advisors first reported a position in Intellia Therapeutics in Q3 2017 and has held it in 24 quarters since.
  • Parallel Advisors's Intellia Therapeutics position peaked at $36K in Q3 2021.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.